Further clinical trial planned for Valneva’s COVID-19 vaccine candidate
Valneva is planning to initiate a further Phase III trial (VLA2001-304) for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
The new VLA2001-304 s...
Continue Reading →
